Constanza Losada, President & CEO, Pfizer Mexico • Interview

As one of the largest manufacturers of vaccines and therapeutics, Pfizer is committed to supporting others in rapidly getting life-saving breakthroughs into the hands of patients as quickly as possible.

“Pfizer is among the global pharma companies that invest the most in R&D.”

What is your mission as Pfizer’s country manager for Mexico?

We have several products for diseases that are unfortunately not well known and, therefore, do not have any treatment options available in the market. By working on rare diseases, we want to improve and save the lives of patients all around the world. The key aspect of our business is figuring out how to help institutional payers reimburse these treatments.

What is the breakdown of your business between the public and private sectors?

Chiesi Mexico does almost 70% of its business with government institutions. Amid the changes happening in the government procurement processes and the delays in tender publications, we are trying to involve ourselves in the new dynamics. It is more complicated than in the past to be involved. The risks can be much higher now, so the companies will have to revise internal procedures and flows to comply with new regulations.

We had the honor of launching TRIMBOW® in Mexico for the first time outside Europe thanks to the agreement between the European Medicines Authority (EMA) and COFEPRIS. The product, already approved by EMA, was immediately recognized by COFEPRIS, which allowed us to carry out everything in a timely fashion.

What new products and services are you planning to launch in Mexico in the coming months?

We will launch the first of our rare disease products, after sorting out the regulatory procedures. This will be the first milestone for Chiesi Mexico in rare disease and will hopefully be the first of a long series of launches over the coming years. We hope to work together with the government to develop sustainable access models. ✖